DATE: March 11, 2009

LOCATION: Holiday Inn – San Diego Bayside
4875 North Harbor Drive
San Diego, CA 92106

BOARD MEMBERS PRESENT: Robert Swart, PharmD, Committee Chair
Stanley C. Weisser, RPh
James Burgard, Public Member

STAFF PRESENT: Virginia Herold, Executive Officer
Anne Sodergren, Assistant Executive Officer
Joshua Room, Deputy Attorney General
Kristy Schieldge, DCA Senior Staff Counsel
Tessa Fraga, Analyst

Call to Order

Chairperson Rob Swart called the meeting to order at 9:31 a.m.

The meeting began with a brief video created by Pfizer, Inc. which reveals the dangers of buying counterfeit medication online.

Dr. Swart provided background on e-pedigree. The 2008 legislative session ended September 30, which is the date when the Governor signed SB 1307 (Ridley-Thomas). This law now staggers implementation of e-pedigree requirements in California away from 2011 to:

- 50 percent of a manufacturer’s products by 2015
- The remaining 50 percent of the manufacturer’s products by 2016
- Wholesalers and repackagers must accept and pass e-pedigrees by July 1, 2016
- Pharmacies and pharmacy distribution centers must accept e-pedigrees by July 1, 2017
Dr. Swart noted that there is preemption language that would repeal California’s provisions if federal law regarding e-pedigrees is enacted, or if federal standards are enacted, they would take effect in California. He also noted that there are provisions that define drop shipments, 3PLs, repackagers and manufacturers. Grandfathering provisions for drugs already in the supply chain are included.

Dr. Swart stated that the board will ultimately have to develop regulations for various components, including inference. No action on these regulations is planned for several years.

**A. Workgroup on E-Pedigree**


Dr. Swart stated that the Enforcement Committee will now have an opportunity to discuss the FDA’s request for comments on “Draft Guidance for Industry on Standards for Securing the Drug Supply Chain -- Standardized Numerical Identification for Prescription Drug Packages”.

Dr. Swart explained that the FDA’s document is fairly broad, but that the content is very similar to comments provided by California in regard to the e-pedigree standards. He stated that the FDA is now requesting additional comments specifically focused on the standardization of numerical identification of prescription drug packages. He noted that the comments are due to the FDA by April 16, 2009 and encouraged all in attendance to submit written comments.

Dr. Swart explained that, under 2007 federal law Federal Food and Drug Administration Amendments Act of 2007 (FDAAA)), the FDA was charged with developing a standardized numerical identifier to be applied to a prescription drug at the point of manufacturing “sufficient to facilitate the identification, validation, authentication, and tracking and tracing of the prescription drug.” He noted that this would be the serialized identifier referenced in California’s e-pedigree law.

Dr. Swart provided his opinion that labeling should be required on all packaging down to the smallest unit and that this is more crucial than the visual appeal of the label.

Dr. Swart reiterated that, at today’s meeting, the workgroup on e-pedigree will have the opportunity to discuss this request for comments and determine whether the board should submit comments in support of the FDA’s identification of this identifier. Also, since the FDA will be attending this meeting, the Workgroup on e-pedigree will be able to ask questions of the FDA regarding this process.
Public Comments:

The committee generally discussed serialization issues. There was some concern regarding the eight-digit serialization number that would be the random portion of the unique identifier, and whether that is a sufficient number size to allow for lack of duplication and reuse over a period of time. The committee agreed that an alpha-numeric identifier for the 8-digit random number would be a better standard.

The committee expressed support for the FDA moving ahead with this standard, nearly one year early.

2. Discussion of Comments for FDA’s Proposed Guidance for Industry on Unique Device Identification (UDI) Systems

Dr. Swart stated that, on February 12, 2009, the FDA convened a hearing on “Unique Device Identification System.” The hearing was convened to enable the FDA to eventually “promulgate regulations establishing a unique device identification system for medical devices requiring the label of devices to bear a unique identifier, unless the Secretary [of Health and Human Services] requires an alternative placement or provides an exception for a particular device or type of device. The unique identifier shall adequately identify the device through distribution and use, and may include information on the lot or serial number.”

Dr. Swart noted that, while California’s e-pedigree requirements exclude dangerous devices, the board still regulates the distribution of dangerous devices within, throughout and into California. He also noted that the issue is being provided for the committee as information and for discussion.

Ms. Herold stated that the FDA will initiate a comment period within the next six months. She also noted that this will affect the Board of Pharmacy and its licensees as they regulate those that sell, ship and store dangerous devices within the state of California.

Public Comments:

Ron Bone (McKesson Corp.) shared that the meeting held in Maryland, hosted by the FDA, was well attended by those within the supply chain. He noted that there were four panels discussing the issues and that submissions were provided following the meeting. The meeting promoted significant focus for UDI systems.

Mr. Room asked Mr. Bone whether he views the UDI requirements as a similar undertaking to e-pedigree.

Mr. Bone responded that, with UDI, the process is much more complicated and has many issues to address. The identification criteria will vary based on product. He also
3. Discussion and Updates to Implement Electronic Pedigree Requirements – Presentations

a. Ilisa Berstein – Food and Drug Administration (FDA)

Dr. Bernstein provided an overview of the Guidance for Industry. She explained that 505D of the FDA Standards Development Act gives the FDA authority to develop standards for identification, validation, authentication, and tracking and tracing. She noted that the FDA is working to have standards finalized for serialization identification prior to the March 2010 deadline. Thus, the January 2009 draft was issued with opportunity for comments from the industry.

Dr. Bernstein reviewed the proposed Standardized Numerical Identifier (SNI), which would essentially result in a Serialized National Drug Code (NDC) as it is a combination of each product’s NDC and a unique eight-digit serial number. She identified specific characteristics of the serialized NDC which were modified based on comments provided by industry.

Dr. Bernstein stated that the draft Guidance was announced in the Federal Register. She provided specific questions submitted by the FDA along with the draft which they are requesting comment on by industry.

Dr. Bernstein provided information for web site links to the draft Guidance Federal Register Notice and instructions for filing comments, which are due by April 16, 2009.

Questions from the Board:

Dr. Swart questioned the decision of excluding the lot number from the SNI. He stated concern about how that will effect patient safety in relation to e-pedigree and recall notification.

Dr. Bernstein responded that the SNI will link to a data base which will provide the expiration date, lot number, etc. She added that the information Dr. Swart is referring to would be a standard of track and trace.

Stan Weisser questioned whether it is feasible at this point in the decision process to reconsider the eight-digit number.

Dr. Bernstein responded that comments will be considered and changes will be made as necessary to the final draft. She added that nothing is final at this point.
Mr. Weisser questioned the FDA’s decision not to address the case and pallet identifiers issue.

Dr. Bernstein responded that the law requires an SNI for pallets. She added that the FDA feels there should be an SNI for cases as well. However, more information is needed before they would be able to provide a recommendation in the future. Therefore, they are seeking comments from industry and are hoping to receive the necessary information.

Mr. Weisser mentioned that it was included in the comments submitted by the Board of Pharmacy.

Dr. Bernstein responded that they did receive some comments and information, but that it was not substantial enough to be able to provide an educated recommendation.

Ms. Herold explained that the board requested in their comments in 2008 that the NDC be part of a serialized number on the individual unit. She noted that the FDA appears to be including that in their Guidance. She stated that the ability to link the serialized number to a particular case or pallet is necessary for the wholesalers.

Mr. Room explained that the board requested that the serialization be included at the unit level, as that is the most crucial. There has been an assumption that, in order for the serialization system to be effective and workable, serialization would need to occur at the case and pallet level as well. He added that the board can choose to reaffirm by submitting additional comments in regards to case and pallet level serialization.

Mr. Weisser referenced the board’s 2008 comments to the FDA. He quoted a section of the letter which states that the board believes that a full track and trace system would require SNI’s on both levels – the individual unit and the case/pallet.

Mr. Room stated that the letter is a reflection of California law. He noted that California law does not state requirements relating specifically to case and pallets.

Ms. Herold added that if inference is allowed in the future, then it may be necessary to address SNI’s at all levels within regulations.

Jim Burgard expressed concern regarding the individual serialization involving eight digits. He stated that, as large quantities of items are serialized, the process will become more complex for manufacturers. Mr. Burgard stated that this complexity should be considered.

Dr. Swart stated that it will be necessary for the manufacturers to provide input on what is the optimal amount of digits within the serialization.

Mr. Weisser reiterated that using only eight numerical digits is a limiting factor.
Public Comment:

Mike Durschlag (Allermed Laboratories) commented that the standards are geared towards identifying drugs in the distribution system. He asked Dr. Bernstein if the same standards will apply when a manufacturer distributes directly to a physician.

Dr. Bernstein responded that that issue is outside the scope of the proposed Guidance and standards and would need to be addressed later.

Mr. Bone (McKesson) asked about the opportunity to have the UDI and SNI on the same package. This would be important for kits, where both a drug and a device are present.

Dr. Bernstein stated this has not been resolved. She did note, however, there has been discussion within both SNI and UDI workgroups on the subject and that they recognize the need for compatibility within the supply chain.

Steve Gray (Kaiser Permanente) asked if there is any significance in the pairing of the numbers within the eight digit structure of the SNI. He referenced the Generic Product Indicator (GPI) used on retail products, explaining that the numbers are paired to provide information on the type of product it is. He also asked if the SNI digits could be developed in a way to provide information on where the product originated.

Dr. Bernstein stated that the Guidance indicates the eight digit number is to be created by the manufacturer or repackager of the product. She added that, except for the requirement that the SNI must be unique for each package, the Guidance does not specify how the number is to be generated. She encouraged such suggested comments to be submitted.

Mr. Room identified that there is tension between those in the supply chain who want the number to have specific representation and those who want the number to be random because of the flexibility it provides. He stated that both GS1 and the FDA have indicated that it is by reference to the database to retrieve such identifying information, rather than by reference to the number itself.

Dr. Gray responded that the user is the consumer, and that they would not have access to the database. He added that consumers want to know where the product comes from, especially in relation to whether the drug originated from a manufacturer in another country. He reiterated his suggestion to consider this within the comments provided.
b.  **Allison Hite - Congressmember Buyer’s Office**

Ms. Hite provided an update on e-pedigree implementation on a federal level. She stated that there is a bit of a standstill with the new chairman of Energy and Commerce. She encouraged any support and influence that any individuals or organizations in California may be able to provide in bringing the issue forward to Chairman Waxman, as the state has a strong representation with regard to e-pedigree of drugs. Ms. Hite stated that legislation at this time is indeterminable as how Chairman Waxman plans to handle food and drug regulation is not known. She indicated that there was a hearing regarding food safety, and foresees two separate bills as a result of that hearing, with food safety being addressed first and drug safety following.  

Ms. Hite noted that they have made significant strides and have attempted to mirror California’s efforts thus far in terms of the timeline of serializing drugs, as well as a track and trace system. Ms. Hite stated that Chairman Waxman is in support of having any related legislation which occurs at the federal level be influenced by legislation which is put in place in California. She explained that they are seeking assistance from the FDA on their legislation before moving forward.  

Ms. Herold noted that, with regard to regulation development, the Congressman’s office has been very clear thus far in not wanting to disrupt any efforts by states with respect to addressing serialization and pedigree. She stated that the early version of the bill seemed to directly follow the California model versus what other states have done. She asked if Congressmember Buyer is going to continue with that plan of following the California model, or if they are waiting for input from Chairman Waxman.  

Ms. Hite responded that the goal is to have one standardized pedigree standard. She stated that they are moving forward with flexibility in the language in order to meet the final goal. She noted that they felt the California timeline is more than adequate for the process.

c.  **Bob Celeste - GS1**

Mr. Celeste provided an update on the standards development and adoption. He reviewed the reason for GS1’s involvement in the serialization and global standardization process.

Mr. Celeste stated that, in order to achieve patient safety and healthcare supply chain efficiency, there are “foundational” steps to be addressed. Those steps include Standardized Product Identification (GTIN), Standardized Location Identification (GLN) and Standardized Product Definition (GDSN). Additionally, Mr. Celeste explained that the “pillars,” which includes track and trace and e-pedigree, are the benefits which build on those foundational steps.  

Mr. Celeste provided definitions for GS1’s standards. He stated that the NDC is embedded within the GTIN number and a serial number is included. He explained that
the GTIN is then placed within a Global Data Synchronization network, where the information about that product can be obtained. Mr. Celeste also explained the creation of the Global Location Number and registry.

Mr. Celeste provided an example of how a product is ultimately tracked through the supply chain by use of identifiers. He added that GS1 is looking at the various issues raised by the pharmaceutical industry relating to traceability adoption and the use of identifiers versus carriers.

Mr. Celeste summarized the comments provided by GS1 to the FDA:

- Pallet and case level – GS1 is suggesting that the supply chain be able to use the serialized shipping container number as well as the Global Returnable Asset Identifier (GRAI)
- Blood and blood products serialization – conflicts with serial number standards
- Requested FDA to consider adopting GTIN’s so that they can be accepted within their system
- Requested FDA to consider a sunset of duplicate data that is automated

Mr. Celeste noted that application identifiers can be added to bar codes.

Mr. Celeste discussed the issue of bar code quality with relation to the use of a verifier, which reads and depicts the quality of a barcode. He explained that a test card is used to ensure that a readable bar code is produced. He explained that a good quality bar code ensures readability and prevents sending bad bar codes into the supply chain.

Mr. Celeste stated that the current pedigree standards allow for reliable movement and disposition, but also contains redundant product and location data. He indicated that, with the use of current and emerging standards, supply chain partners will have:

- Reliable product descriptions
- Reliable location hierarchy
- Reliable lookup and authentication

Mr. Room questioned whether the intent is for the data to be “pushed down” at each level, creating a static database at some point.

Mr. Celeste responded that China, for example, does not want their data in a US database. Therefore, the standards accommodate multiple Discovery Services.
Mr. Room asked if there would be a loophole for reliability of individual recipient data in that situation.

Mr. Celeste responded that the equivalence between the system and e-pedigree needs to be discussed further.

Mr. Weisser asked how manufacturers can protect their data from regions with more loose systems that allow for the potential of counterfeiting.

Mr. Celeste responded that the negotiations between Discovery Services and authentication procedures, as well as agreements that need to take place are involved and time consuming. He added that there is no guarantee that counterfeiting in another country would not occur, but noted that manufacturers have control over where they store their data. Mr. Celeste added that, currently, only the US is interested in having multiple Discovery Services, so it would only involve domestic pharmaceuticals and medical devices.

Mr. Celeste explained that an inference paper is being written and is currently in draft mode. He explained that the paper will discuss the general uses of inferences, how inference is currently being used, and risk mitigation. Mr. Celeste noted that the paper will take one more month for completion and provided a brief summary of what the inference paper encompasses. He noted that the paper will be finalized within a month to be published.

Mr. Celeste stated that GS1 is currently working on the subject of Radio Frequency Identification (RFID) with relation to providing supply chain security and privacy. They are also reviewing the business benefits of serialization and granular events. Mr. Celeste explained that this refers to the specific benefits to the supply chain, as well as patient safety, once serialization is in place.

Mr. Room asked if Mr. Celeste could provide insight to support why the FDA should adopt the GTIN as the standard for serialization.

Mr. Celeste responded that many countries have already adopted GTIN as the standard. He explained that the adoption to strictly GTIN (rather than native GTIN) would involve a lengthy conversion process. He added that the first step is to register a GTIN. Mr. Celeste referenced the peanut butter recall and how the standards were misused. He added concern over the difficulties in obtaining medication bedside within hospitals.

Mr. Room asked for a projected impact in using the SNI relating to global compatibility and distribution.

Mr. Celeste responded that there are currently explicit difficulties, as the NDC is only accepted within the US.
Public Comments:

Steve Gray (Kaiser Permanente) referenced his earlier comment regarding the consideration by FDA to have the SNI be assigned digits that reflect its origin, for example, rather than being randomly assigned. He pointed out that, unlike other products such as clothes or toys, there is no way for a consumer to identify whether their prescription drugs were manufactured in another country.

Mr. Celeste responded that the GLN would identify where the item was manufactured. He also stated that one of their application identifiers is the country of origin. Therefore, a bar code can provide the information as Dr. Gray is suggesting. He added that it is up to the supply chain to decide what is included within the bar code.

Dr. Gray asked if GS1 sees the multiple Discovery Services referenced as an entity that would need to be licensed by the FDA or government regulated.

Mr. Celeste responded that he is unsure. He stated that discussions are needed to determine what process is necessary in order for Discovery Services to be trusted in terms of legitimacy and security of data.

Dr. Gray asked if proprietary privacy is also being incorporated into the discussions on security and privacy.

Mr. Celeste responded that discussions relating to proprietary privacy within the network are taking place.

d. John Danese - Oracle

Mr. Danese provided a presentation on Oracle’s drug supply chain integrity strategy. He noted that a presentation was made by Oracle to the board one year ago immediately prior to the deadline extension. Mr. Danese stated that, at that time, Oracle was not ready for a 2009 deadline, and that the extension to 2011 allowed Oracle and its customers the time needed to be fully prepared with implementation. Mr. Danese also provided a brief background on the company.

Mr. Danese reviewed the main “drivers” of the direction Oracle is taking in their strategy. They are:

- The US States – CA e-pedigree law now 1/1/15 and federal preemption language
- US Federal – FDA Amendments and Globalization Act
- Europe, Middle East and Africa (EMEA) – Countries are developing serialization databases and initiatives independently
- GS1 Healthcare – global traceability standards
Mr. Danese added that their customers are focused on product serialization as it is being addressed in Europe. He stated that Oracle has placed focus on their initial product release in terms of the serialization aspects, and indicated that they have taken a “wait and see” approach to see how the pedigree requirements evolve.

Mr. Danese explained that Oracle has been meeting regularly with a customer focus group in order to collaborate on the design of their product. He stated that, as a result of those meetings, they have been able to identify three main types of responses on what manufacturers are currently doing to prepare for implementation. Those are:

- Forge ahead with serialization efforts and lighten up effort around pedigree
- Refocus on European Union products and serialization
- Wait and see approach – putting projects on hold and doing nothing actively

Mr. Danese also provided specific responses from their customers, both large and smaller pharmaceutical companies, in relation to the current status of e-pedigree and serialization as well as how to address the European markets and their requirements.

Mr. Danese pointed out that the urgency around serialization remains high, based on a survey of their customers. He added that many are continuing with their serialization efforts, which is what drives Oracle’s product development.

Mr. Danese reviewed the business benefits in addition to regulatory compliance, which includes product and channel integrity, regulatory compliance and better management of returns. He noted that returns are a huge cost. He emphasized that serialization allows a link between the return receipt and the original shipment/invoice, thus reducing the opportunity for illegitimate products being returned.

Mr. Danese provided information on a new product, the Oracle Pedigree and Serialization Manager (OPSM), which will be developed to ensure supply chain integrity. He explained that the software application will enable companies to implement mass-serialization of drug products and share serialized product data. Mr. Danese stated that the product will protect public health, achieve compliance with global electronic pedigree and related regulations, protect brand integrity and provide cost savings.

Mr. Danese stated that a partner/consumer serial validation portal will be provided so that manufacturers will get additional views into where their product is consumed while customers will be able to serial authenticity, check for recalls, etc.

Mr. Danese addressed the prior questions from the board and public regarding cases and pallets being serialized and unique identifiers for those levels. He explained that the OPSM will be able to generate the unique identifiers for product packaging at the smaller saleable unit levels (blister packs, boxes and cases). The system will not provide serialization on the pallet and container unit level. Those numbers can, however, be accepted from a warehouse management system and be captured as part of their packaging hierarchy. Mr. Danese noted that the OPSM will allow for cross-
referencing of codes (GTIN, GTIN, UPC) at each unit level, so that multiple identification numbers can be used.

Mr. Room asked if Oracle plans to submit FDA comments on the issue of the serialization number.

Mr. Danese responded that they have provided comments on the standards. He does anticipate that they will provide comments on the unique identifier aspect as well.

e. Other Interested Manufacturers, Wholesalers, Pharmacies and their Associations

No other comments from manufacturers, wholesalers, pharmacies and associations were provided.

Ms. Herold requested that the board provide additional comments to the FDA on this subject. She noted that the comments are due prior to the next board meeting. She suggested that the Enforcement Committee Chair collaborate with the Board President to determine additional comments to the FDA, addressing the issue of the quantity of digits and whether an eight digit format will be sufficient for the needs of the supply chain. She added that she feels comments should also be provided by the board in support of a unique identifier at the case and pallet level, as the board will be required to develop regulations on inference, but that the board should not be specific as to what the unique identifier should look like because they do not have the knowledge to determine that.

Mr. Room added that the board is pleased to see the FDA taking the same approach as required by California law to focus on serialization at the unit level first.

Motion: Dr. Swart and President Schell to collaborate and submit additional comments to the FDA on the board’s support of the unique identifier at the case and pallet level as well as a potential format in terms of quantity of digits and alphanumeric layout.

MOTION: SW/JB

SUPPORT: 3   OPPOSE: 0

B. Enforcement Committee

1. Discussion of Policies Involving Home Generated Pharmaceutical Waste Take-Back by Pharmacies

Dr. Swart provided background on drug take-back programs. He explained that last year, SB 966 (Simitian, Chapter 542, Statutes of 2007) directed the California Integrated
Waste Management Board (CIWMB) to develop the parameters for “model” drug take-back programs in pharmacies. These model programs are intended to provide consumers with the ability to dispose of unwanted prescription and over-the-counter drugs (but NOT controlled substances) without flushing them down the toilet or tossing them into the garbage. Under SB 966, these guidelines were to be in place by December 2008.

Dr. Swart explained that state and federal law regulates prescription medicine until it is dispensed to patients. It is not regulated again unless it is collected at consolidated points, at which point it becomes medical waste, and must be handled and destroyed in specific, mandated ways.

Dr. Swart stated that patients are often confounded about what to do with unwanted medicine. Californians increasingly want “green” options for disposing of unwanted medicine, which current law does not allow. He added that there is no viable process, other than to make the discarded drug products unpalatable (mixing with kitty litter or other substance, wrapping in duct tape, etc.) and then placing them in the trash. Dr. Swart noted, however, that some drugs may be flushed down the toilet, and are specifically labeled by the manufacturer to dispose of in this manner.

Dr. Swart indicated that pharmacies have in some cases agreed to take back unwanted drugs from patients. However, this acquisition by pharmacies is not authorized in law. He advised that some communities periodically offer community take-back events, or special days at landfills where the public can take back drugs.

Dr. Swart explained that some drug manufacturers (and the state of Maine, where there is a pilot program underway) provide mailers that patients can use to send unwanted medicine to a predetermined location for destruction. This is the process preferred by the DEA for controlled drugs.

Dr. Swart emphasized the greatest problem for the board with drug take-back programs, which is the potential for these drugs to be diverted to the streets. He stressed that there is a serious prescription drug abuse problem in the US, and the uncontrolled aggregation of prescription medicine is an attractive enticement. In some cases, drugs collected in bins could re-enter the prescription drug supply if pharmacies or wholesalers (or others) sell these items back into the supply chain.

Dr. Swart pointed out that pharmacies are areas where health care is provided. He shared that concern has been expressed that it is difficult for this purpose to be combined with a recycling center, where high sanitation is not necessarily a priority.

Dr. Swart stated that pharmacies have also expressed concern that they may be required to absorb the costs of paying for disposal of these returned drugs, for sorting out controlled drugs (which potentially would require a pharmacist’s time) and for assuring the safety and periodic emptying of collection bins.
- Model Guidelines for Home Generated Pharmaceutical Waste Approved by the California Integrated Waste Management Board (CIWMB)

At the January 2009 and October 2008 Board Meetings, the board discussed concern with the proposed model program guidelines as drafted by the California Integrated Waste Management Board. However, the board did express its support for such programs on a voluntary basis with appropriate, specified safeguards.

Ms. Herold provided the board's concerns with provisions in the draft model program guidelines at a committee meeting of the Integrated Waste Management Board (CIWMB) on November 10. Specifically, Ms. Herold stressed the opinion of the board that the program should be established as voluntary.

Dr. Swart stated that, on November 13, the CIMWB adopted the Model Guidelines without incorporating the additional changes listed in the board's November letter. However, a number of other entities also provided comments to guidelines. For this reason, the CIWMB agreed to consider modifications to the Model Guidelines at its February 2009 meeting.

Ms. Herold again provided written comments and testified to the CIWMB on February 18.

- Senate Bill 26 (Simitian)

Dr. Swart indicated that Senator Simitian has introduced SB 26, which would direct the board to coordinate with other state agencies, local governments, drug manufacturers and pharmacies to develop sustainable efficient policies to manage pharmaceutical waste and the disposal of devices.

- Comments Sought by the Federal Drug Enforcement Administration on Disposal of Controlled Substances by Persons not Registered with the DEA – Docket No. DEA-316A

Underlying what is a national problem about how to deal with unwanted and unused drugs, the Drug Enforcement Administration is currently seeking comments on “Disposal of Controlled Substances by Persons Not Registered with the Drug Enforcement Administration.” Dr. Swart advised that comments for this item are due March 23, 2009.

Ms. Herold explained that there is a new Integrated Waste Management Board. She stated that they view take-back drugs as a good thing, and are open to discussions on funding. Ms. Herold indicated that there are two versions of model guidelines available. There is question as to whether the guidelines will be feasible for the board to enforce. SB 26 provides amendments to address those issues.

Dr. Swart noted that the law to date has prohibited the take-back of drugs.
Ms. Herold responded that SB 26 addresses this issue and that provisions have been made.

Dr. Swart encouraged industry comments.

Ms. Herold shared that pharmacists are not to accept controlled drugs that are returned. Instead, only law enforcement can accept these items. The involvement of the DEA in establishing policy in this area is another indicator of the movement underway to provide green methods of disposing of unwanted pharmaceuticals.

Ms. Herold encouraged the board to provide comments to the DEA on this topic.

Dr. Swart suggested that the board provide input to Ms. Herold and board staff, which will in turn provide the comments to the DEA.

Discussion continued regarding drug take-back with respect to accountability and return receptacles.

Public Comments:

Dr. Gray (Kaiser Permanente) stated concern over this issue gaining publicity and leading to confusion and misinformation. He indicated that, aside from general confusion, there are actually two problems with relation to diversion of the unwanted and returned drugs. Not only might the drugs be resold by pharmacies or wholesalers, but they are sometimes also being gifted to non-profit programs, which is prohibited by law. Dr. Gray suggested that efforts be made to coordinate information provided by the DCA Boards. He also suggested that FDA coordinate their responses with those of the California Board of Pharmacy.

Ms. Herold stated that the DEA is moving in the right direction to stop this, but she is concerned about pushing the DEA too much on this topic. Unwanted drugs within long-term hospice care are the biggest concern, which is the DEA’s focus.

In response to coordination of the other boards within DCA, Ms. Herold stated that she has been asked to meet with the other boards to discuss take-back and provide updates. She added that the donation of drugs is apparently not an issue.

There was discussion in relation to drug samples, and Ms. Herold stressed that pharmacies are not to take back drug samples.
Motion: Draft comments to the DEA regarding the disposal of controlled drugs by persons not registered with the DEA.

M/S: JB/SW
SUPPORT: 3    OPPOSE: 0

2. Update on Activities to Implement E-Prescribing in California

Dr. Swart explained that a number of patient and health care advocates have strongly pressed the need for increased use of e-prescribing. He stated that a principal reason is that statistics indicate that medication errors cost the health care system $77 billion and cause 7,000 deaths annually. Dr. Swart stressed that a number of these errors could be prevented by full implementation of e-prescribing. Other savings have been projected from redirected time currently spent by prescribers and pharmacies in verifying and switching prescription orders.

Dr. Swart stated that by the mid-1990s, the board had sponsored legislation and promulgated regulations to ensure that e-prescribing was authorized in California law. Since then, various provisions have been added or amended to keep law supportive of allowing electronic prescriptions. He noted that a current deterrent is that controlled substances cannot be e-prescribed. This has caused additional problems and limited the usefulness of e-prescribing within doctor’s offices. Dr. Swart indicated that the DEA provided guidelines in the past on the subject, which only made the process more cumbersome.

Dr. Swart advised that, on November 20, 2008, the Board of Pharmacy hosted an e-prescribing forum in conjunction with the Department of Consumer Affairs’ Professionals Achieving Consumer Trust Summit. He noted that the other healing arts boards whose licensees prescribe drugs attended this forum, as did our stakeholders and public interest groups. The Dental Board and Medical Board joined the forum as partners.

Dr. Swart noted that the California HealthCare Foundation (CHCF) is strongly advocating adoption of e-prescribing. They also hosted a November 20 forum in San Francisco on e-prescribing.

Dr. Swart explained that, since then and among other projects, the CHCF has been working with the executive staff of the Medical Board and the Board of Pharmacy to host a series of statewide events where physicians and pharmacists could earn continuing education (CE) credits and simultaneously work through issues limiting adoption of e-prescribing. The CHCF is currently in the discussion phase and hope to have a “road show” they can take throughout California in the next few months.

Ms. Herold added that there is a forum scheduled for Visalia at the end of March. There will be two sessions on that day, with members of the Medical Board and physicians scheduled to attend. Additional forums to allow physicians and pharmacists the
opportunity to discuss and collaborate on the issues limiting the adoption of e-prescribing which will occur throughout the remainder of the year. The board has been asked if it is interested in participating and if so, the board will grant CE to pharmacists who attend these events. The Medical Board has already agreed to do this for their licensees. Ms. Herold will work on arranging for Board of Pharmacy licensees to be able to receive CE for attending the event.

Dr. Swart reiterated his support for providing CE to those who attend.

Additionally Assembly Bill 718 has been introduced to require all prescribers and pharmacies to have the ability to transmit and receive prescriptions by electronic data transmission. Dr. Swart noted that the sponsor of this bill is a technology firm, Reed Elsevier, Inc.

Dr. Swart stated that he was concerned about smaller pharmacies, as well as those located in rural areas, being able to comply with the ability to e-prescribe.

Ms. Herold provided information that the Governor’s Healthcare Initiative has the same deadline of January 1, 2012, which will affect every prescriber and every pharmacy and thus will have wide impact.

There was discussion on the language of the legislation and the potential for enforcement discretion by the board and staff, as there is no specific consequence for the inability to e-prescribe.

Dr. Gray (Kaiser Permanente) noted that this is only a preliminary version of the bill and pointed out that it may evolve. He stated that federal law is already in place which establishes the standards and parameters for e-prescribing and transmission through the National Council for Prescription Drug Programs (NCPDP). He added that those may become the standards required in order for an entity to claim that they have the ability to e-prescribe. He also mentioned the incentives and penalties for e-prescribers if they are involved (or not) in federal billing. Dr. Gray added that this law will pertain to all prescribers. He raised the question of who would be the actual enforcement entity. Dr. Gray stated that there may be a requirement for the board to adopt regulations to further define what will be in effect by 2012. Dr. Gray recommended that future action in regards to this bill be discussed at the next Legislation and Regulation Committee meeting.

MOTION: To grant continuing education credit to licensees who participate in the events being held by the California Health Care Foundation throughout California.

M/S: RS/JB

APPROVE: 3  OPPOSE: 0
3. California’s Controlled Substance Utilization Review and Evaluation System (CURES), a presentation and question and answer session led by the Department of Justice, Bureau of Narcotics Enforcement

Dr. Swart explained that, in mid-December, the board and California pharmacies were advised that effective January 1, 2009, the California Department of Justice would have a new data collection vendor for CURES, and that all California pharmacies were to submit data to this new vendor beginning January 1, 2009. He pointed out that this was a short transition, and the board has learned that some pharmacies are having transmission issues.

Kathy Ellis (Department of Justice – Bureau of Narcotic Enforcement “CURES” division) provided an overview and explanation of the CURES program, including the use of a vendor who collects the data submitted by pharmacies to create a database used by practitioners. Ms. Ellis discussed the recent change to a new data collection vendor after having the same vendor for the past 10 years. She explained that the State of California required them to go out for bids for a new vendor and that the turnaround time for switching vendors was very short. Ms. Ellis concurred with industry feedback that the transition has not been seamless as expected.

Ms. Ellis provided history on the development of the CURES and the program’s database. She noted that, as a lesson learned in the recent transition, a turnaround in contracts is necessary in the future.

a. Implementation Issues Surrounding the New Data Collection Vendor for CURES

Ms. Ellis explained that, after implementation, many errors were noticed in the vendor’s program. Specifically, the main issue was that the Department of Justice (DOJ) was receiving data in invalid formats. Additionally, there were errors involving patients’ date of birth and gender. Ms. Ellis pointed out that the validation criteria have since been corrected to ensure erroneous input of those statistics will not be accepted.

Ms. Ellis indicated that the vendor has been tracking the complaint calls coming in because of the errors, and provided a log to the DOJ. Additionally, she noted that the vendor is receiving a large amount of faxes for data submissions; some which are numerous pages in length. She referenced pharmacy law regulations which state that if a pharmacist is providing more than twenty-five prescriptions within a six month period, they are to be sent electronically.

Ms. Ellis emphasized that they are working with the vendor to correct the issues. She stated that the DOJ is now receiving more data than they are rejecting, which is significant improvement. She also indicated that a letter will be sent to pharmacists in the near future to detail the implementation issues she has reviewed. Ms. Ellis indicated that the letter will stipulate a grace period to allow software vendors to make modification for the new vendor’s format.
b. Moving to Provide Online, Near Real Time Reports to Practitioners on Controlled Substances Dispensed to Patients by July 1, 2009

Ms. Ellis stated that their automation project, which will automate the Patient Activity Report (PAR), will be rolling out in July, 2009. She explained that this will result in allowing authorized practitioners, prescribers and pharmacists to have access to patient activity information via web browser 24 hours a day in “real time.” She noted that the project, which began in 2003, is currently in the test phase.

Ms. Ellis indicated that a notification system will also be rolled out. The alert system will be state wide and will allow for notifications to prescribers, physicians and pharmacists, on a voluntary basis, when there are potential doctor shoppers, theft, forgeries, inappropriate call-ins, etc. in their area

Ms. Ellis reviewed other projects in progress, but explained that the timeline for completion and rollout is unknown as they are dependent on funding and grant money. One such project is the “Direct Dispense”, which will impact practitioners and veterinarians and allow them to enter their data online via web browser rather than sending it manually. Ms. Ellis added that another project in progress involves automation for an on line system for “0 fill” reporting when a pharmacist has no data to report. Ms. Ellis also indicated that integration is being developed to allow providers within hospitals to review patients’ records during an office visit and have instant information on any controlled substances that have been prescribed and dispensed to that patient. She also noted a nationwide prescription drug program that is being developed which will result in a hub for prescribers to be able to share information between states.

Ms. Ellis concluded that by sharing that the automation of the PAR is in final testing stages at this time. Following testing, the DOJ will attempt to pilot the program by finding pharmacists and practitioners who would be willing to run test data prior to the actual rollout. She provided contact information for those who may be willing to assist with the pilot testing of the program.

Questions from the Board:

Dr. Swart asked if the formatting issues currently being seen with the CURES database are primarily preventable when the pharmacists are on the correct format.

Ms. Ellis confirmed, but that the vendor is also responsible for some of the formatting issues as well. She gave examples of relevant formatting issues that have since been addressed with the vendor.
Dr. Swart commented that he is hearing fewer complaints about the system. He clarified that most of the current errors are relating to the format being input by the users.

Ms. Ellis confirmed and noted that some pharmacists are providing data in the format as required by the 2005 ASAP format of the prior program. She added that the validation process has been “relaxed” as she has discussed the requirements in length with the vendor.

Mr. Weisser asked if there has been disruption in patients getting their medications

Ms. Ellis responded that there has not.

Ms. Herold referenced the reports provided by Ms. Ellis which list the formatting issues and database errors that were identified. She asked specifically about the errors relating to an invalid pharmacy identifier and asked whether those incidents would lead to lost data.

Ms. Ellis responded that they were losing the data initially, but that it was corrected within a couple of weeks.

Ms. Herold asked if the formatting issue has been corrected. She voiced concern over whether that data is making it into the database if that entry error can still be allowed to occur.

Ms. Ellis explained how an error message would be sent to the user as a result of the invalid entry. Those error messages resulted in a very high volume of calls to the DOJ. Ms. Ellis stated that the new letter being drafted to pharmacists will explain that adjustments have been made in the program which will remove the errors messages and that the data has, in fact, been collected and accepted into the database.

Ms. Herold asked if there is anything the board needs to share with pharmacies that would help reduce the amount of errors. She stated that the letter being drafted by the DOJ can be sent out via a subscriber alert. Ms. Herold asked if pharmacists can assume that the data being submitted is collected and accurate at this point.

Ms. Ellis confirmed that they can. She added that the earlier data that was rejected was saved and the vendor has been instructed to “rerun” that data in order to add it to the database.

Ms. Herold asked how the board can assist with informing pharmacists of the appropriate format that the data must be submitted, how they should clarify if there is a valid error occurring and who to contact for assistance with those errors.

Ms. Ellis responded that the DOJ will share the validation criteria with the pharmacists. She added that warnings will be given for user input error until July 1, 2009. Beyond
that, user errors on required data fields will be rejected, with a correction required and resubmitted within 14 days.

Ms. Herold stated that the report can be placed on the board website.

There was discussion as to whether pharmacists would have the required software as there is an issue with regard to proprietary software.

Ms. Herold asked Ms. Ellis if the letter is going through review at this point.

Ms. Ellis confirmed.

Ms. Herold stated that she wants to support the CURES program and assist in ensuring that pharmacists are clear on the data format requirements, as the program is such a valuable tool. She indicated that they will not take any action at this point while the DOJ moves forward with distribution of their letter. She reiterated that DOJ should contact the board if there is anything they can do to help.

Mr. Weisser asked about the likelihood of switching to a new vendor in the future.

Ms. Ellis responded that it is always a possibility. She explained that the new vendor was chosen because they were below the cost of the current vendor in the bid process. She stated that prescription monitoring programs are growing nationwide and want to be a part of the bidding. Ms. Ellis emphasized that CURES is taking the necessary efforts to avoid the aggravation that occurred with the recent transition of the new vendor.

Anne Sodergren asked how current the data will be when a user accesses the data once the “real time” automation project is in place.

Ms. Ellis responded that the new vendor uploads the submitted data several times a week.

Ms. Sodergren asked where the information comes from that will be provided in the notification alert system.

Ms. Ellis responded that it comes directly from the source. An example of one such source is from physicians calling and providing the information.

Ms. Herold asked if there is any lag in inputting the information being reported by prescribers as required by them.

Ms. Ellis confirmed that there is lag.

Ms. Herold asked if there is a “clear picture” of those people who are “doctor shopping.”
Ms. Ellis responded that there is not. She stated, however, that staff workload should be reduced as a result of additional automation, which will allow for the opportunity to catch up on the input of information provided by pharmacists.

Ms. Herold asked if the Medical Board is involved in identifying prescribers who don’t submit to CURES.

Ms. Ellis responding that she is unsure.

Public Comments:

Janice Dang, Supervising Inspector, asked if the notification system can include physicians whose registration license has been revoked.

Ms. Ellis responded that she would need to discuss the addition with the IT department. She noted that they do obtain information from the DEA weekly which provides data on registrants whose licenses have been revoked, expired, etc. She agreed that the information would be valuable, but indicated that the DEA data is nationwide and, thus, may not be useable due to its large volume.

Ms. Dang referenced the CURES reports and explained that, with regard to compounding of controlled drugs, the active ingredient is not included or displays as “unknown” She asked if there is a way to reject those entries with an error message to the user.

Ms. Ellis responded that this is a requirement within the data entry to identify what the main ingredient of the controlled substance is. She reiterated that this is a requirement, but they are not getting the data accurately. CURES is trying to correct this issue.

Dr. Gray commented that Kaiser has experience with the DEA list which provides the information on expired, suspended and revoked licenses. He pointed out that there are several subcategories related to the reasons for a revoked license. Dr. Gray also stated that an expired DEA registration does not mean that the registrant is no longer authorized, as it may be due to delays in renewal processing. He noted other variances in expired registration. He stated that caution should be applied if CURES overreacts on such matters as it may affect patients.

Ms. Ellis responded that this was another validation issue. She also stated that, in the case of a DEA expired license, the vendor was originally rejecting the entry. CURES instructed them to stop rejecting those types of entries and to collect the data.

Dr. Gray noted the lag time within the DEA database which need to be taken into consideration as well.
5. Update Regarding Arrests and Criminal Convictions of Board Applicants and Licensees

Dr. Swart explained that the public and board licensees expect the board to act to remove from practice or deny licensure to those with substantially related convictions.

Dr. Swart stated that, as part of the board’s regulatory process, the board requires fingerprint background checks on all applicants. In addition, the board recently implemented a change to the renewal forms for all individual licensees requiring self-certification of criminal convictions or discipline imposed by other regulatory agencies as part of the renewal process.

Dr. Swart pointed out that, in recent years the board has become inundated with fingerprint results. Whereas in 2000/01 the board received 608 arrest and conviction notifications, in 2007/08 the board received over 3,000. Additionally, Dr. Swart pointed out that about 30% of individual renewal applicants fail to complete the self-certification on the renewal form.

Dr. Swart indicated that, when it became clear that the board could not address this increased workload with existing resources, the board submitted a request to increase board staff through the Budget Change Proposal process. Board staff was recently advised that their request to establish a Criminal Conviction Unit was approved and included in the Governor’s budget. Dr. Swart stated that the unit will consist of 6.5 positions and will be responsible for completing investigations on applicants and licensees who are either arrested and/or convicted of a crime and to determine if the arrest or conviction is substantially related to the duties and functions of the license obtained and therefore warrants action by the board.

Dr. Swart advised that board staff has begun recruitment to fill some of the Criminal Conviction Unit positions; however will not be able to fully staff this unit until July 2009, when the board’s budget will be augmented to fully fund the unit.

Dr. Swart added that, more recently, SB 389 (Negrete McLeod) was introduced. He explained that this legislative proposal requires all specified agencies, including the board, to require state and federal level criminal background checks for all applicants as well require all licensees who have not previously undergone state and federal criminal background checks, to complete that as a condition of renewal.

Dr. Swart shared that this is going on throughout the Department of Consumer Affairs. He explained that there are approximately 150 pharmacist licensees who were licensed prior to the fingerprinting requirement established in September, 1949. He stressed that the Board of Pharmacy has moved further along than other boards in completing criminal background checks on licensees who were not previously conducted.
6. Department of Consumer Affairs’ Policies Regarding Pursuit of Interim Suspension Orders Discussion

Dr. Swart explained that on December 15, 2008, the Deputy Director of Legal Affairs for the department, Doreathea Johnson, issued a memo reiterating the department’s policy to encourage the practice of licensing agencies to use Interim Suspension Orders (ISO) and PC 23s when the conduct of a licensee is such that the board cannot afford to wait for the completion of the administrative process, before taking action to ensure the safety of the public. He added that the memo directs all DCA licensing agencies to institute procedures for ordering interim suspension orders as warranted as well as to make recommendations regarding specific conditions when the agency shall pursue a suspension via a PC 23. The memo further provides suggested parameters.

Dr. Swart stated that the board uses all legal actions authorized, including both ISOs and PC 23s when a case is egregious and immediate public harm is eminent. With the implementation of the Criminal Conviction Unit we anticipate an increase in the number of such actions as the board will have sufficient resources to more promptly address violations that warrant immediate suspension.

Dr. Swart advised that the board had received five PC 23 suspensions over the last fiscal year as appropriate, and that they are using them as encouraged.

Mr. Room stated that the low number of ISO’s should not reflect poorly on the board. He added that, in his opinion, ISO’s are typically used only in very specific and constraining circumstances. He noted that it is often more cost effective to go straight to the accusation and have a speedy hearing.

7. Public Comment for Items Not on the Agenda

The meeting was adjourned at 2:34 p.m.
FDA Standards Development (New 505D of the Act)

• Secretary shall prioritize and develop standards for
  – Identification
  – Validation
  – Authentication
  – Tracking and Tracing

• Serialization (Identification) deadline: March 2010
Proposed Standardized Numerical Identifier (SNI)
Serialized NDC

Example of a serialized National Drug Code (sNDC)

<table>
<thead>
<tr>
<th>NDC</th>
<th>SERIAL NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>55555 666 77</td>
<td>11111111</td>
</tr>
</tbody>
</table>

- Expiration date and/or lot or batch number – not included
- No recommendation for data carrier
- Machine and human readable
- Compatible with GS1 serialized GTIN
Additional issues for comment

• What about SNI for case and pallet?
• Alpha-numeric?
• Blood and blood components – ISBT 128 or Codabar?
Important Info

- **Draft Guidance:**
  [www.fda.gov/oc/guidance/drugsupplychain.html](http://www.fda.gov/oc/guidance/drugsupplychain.html)

- **Federal Register Notice:**
  - 74 FR 3054  January 16, 2009
  [http://frwebgate3.access.gpo.gov/cgi-bin/PDFgate.cgi?WAISdocID=7095088148+0+2+0&WAISaction=retrieve](http://frwebgate3.access.gpo.gov/cgi-bin/PDFgate.cgi?WAISdocID=7095088148+0+2+0&WAISaction=retrieve)

- **Comments due: April 16, 2009**
  - [www.regulations.gov](http://www.regulations.gov)
  - Docket:  FDA-2009-D-0001
Who is GS1?

GS1 is a not-for-profit organization dedicated to the design and implementation of global standards to improve the efficiency and visibility of supply chains globally and across sectors.

- 108 member organizations
- 35 years of experience
- Neutral platform for all supply chain stakeholders
- Over a million companies doing business across 150 countries
- Over 6 billion transactions a day

GS1 is the most widely used supply chain standards system in the world.
GS1 Around the World

108 Member Organizations
150 Countries Served
The package has:

- 6 machine readable codes (5 bar codes, 1 data matrix).
- 17 flags (UK, Ireland, Malta, Netherlands, Belgium, Germany, Austria, France, Spain, Portugal, Greece, Cyprus, Norway, Sweden, Denmark, Iceland, Finland) (not Italy)
- 12 different language texts (English, French and German are used in more than one country).
The package has:

- 6 machine readable codes (5 bar codes, 1 data matrix).
- 17 flags (UK, Ireland, Malta, Netherlands, Belgium, Germany, Austria, France, Cyprus, Norway, Sweden, etc. (not Italy))
- 12 different language texts (English, French and German are used in more than one country)

Imagine what this could do to supply chain processes
Contents

• The Fundamentals

• Significant Events

• Quality

• Pedigree future (DPMS, EPCIS, Discovery)

• Business Benefits and New Processes
Building Patient Safety

Healthcare Supply Chain Efficiency

- Standardized Product Definition (GDSN™)
- Standardized Location Identification (GLN)
- Standardized Product Identification (GTIN™)

- Automatic Data Capture (Bar Codes, Data Matrix, RFID)
- e-Commerce (EDI / XML Transactions)
- Electronic Record Management (e-Records, e-Prescriptions)
- Assets & Equipment Tracking
- Traceability (e-Pedigree, Recalls)

Standardization ➔ Interoperability
Building Patient Safety

The Fundamentals

Track & Trace Built on a Strong Foundation of the Fundamentals

- Automated Data Capture (Bar Code, Data Matrix, RFID)
- Electronic Record Management (e-Records, e-Prescriptions)
- Assets & Equipment Tracking

Standardized Product Definition (GDSN®)
Standardized Location Identification (GLN)
Standardized Product Identification (GTIN®)
STANDARDS IN ACTION

GTIN  EPCIS  GLN
GDSN

DISCOVERY SERVICES

GLN REGISTRY FOR HEALTHCARE
STANDARDS IN ACTION

Definitions

• GTIN® (Global Trade Item Number)®
• GDSN® (Global Data Synchronization Network)®
• GLN (Global Location Number)
• EPCIS (EPC Information Services)
NDC ➔ GTIN:
(01) 00314141999995
NDC ➔ GTIN:
(01) 00314141999995
SERIAL NUMBER: 165APX3E
NDC ➔ GTIN:
(01) 00314141999995
SERIAL NUMBER: 165APX3E

SN:
MANUFACTURER:
GTIN: (01) 00314141999995
RAND
TRENGTH: 25mg
000 PILLS
TC

GDSN:
Global Data Synchronization Network
## GS1 STANDARDS IN ACTION

### GDSN:
- MANUFACTURER
- GTIN: (01) 00314141999995
- BRAND
- STRENGTH: 25mg
- 1000 PILLS
- ETC

### STATIC DATA

**NDC ➔ GTIN:**
(01) 00314141999995

SERIAL NUMBER: 165APX3E

---

### DYNAMIC DATA

<table>
<thead>
<tr>
<th></th>
<th>2/1/09</th>
<th>2/15/09</th>
<th>3/1/09</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHIP FROM</td>
<td>MANUFACTURER GLN - A</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
</tr>
<tr>
<td>SHIP TO</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td>RETAIL STORE GLN - D</td>
</tr>
<tr>
<td>RECEIVED DATE</td>
<td>2/8/09</td>
<td>2/20/09</td>
<td>3/10/09</td>
</tr>
</tbody>
</table>

---

**GLN:**
Global Location Number

---

© 2008 GS1 US
**GDSN:**
- MANUFACTURER
- GTIN: (01) 00314141999995
- BRAND
- STRENGTH: 25mg
- 1000 PILLS
- ETC

**STATIC DATA**

**GTIN:**
(01) 00314141999995

**SERIAL NUMBER:** 165APX3E

**DYNAMIC DATA**

<table>
<thead>
<tr>
<th>SHIP DATE</th>
<th>MANUFACTURER GLN - A</th>
<th>WHOLESALER GLN - B</th>
<th>RETAIL CHAIN WAREHOUSE GLN - C</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/1/09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2/15/09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/1/09</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SHIP TO</th>
<th>WHOLESALER GLN - B</th>
<th>RETAIL CHAIN WAREHOUSE GLN - C</th>
<th>RETAIL STORE GLN - D</th>
</tr>
</thead>
<tbody>
<tr>
<td>RECEIVED DATE</td>
<td>2/8/09</td>
<td>2/20/09</td>
<td>3/10/09</td>
</tr>
</tbody>
</table>

**GLN Registry for Healthcare®**
- GLN - B (1100004570208)
- WHOLESALER NAME
- ADDRESS
- PHONE NUMBER
- ETC
### Manufacturer’s Database
- **GTIN**: (01) 00314141999995
- **SERIAL NUMBER**: 165APX3E
- **PRODUCTION DATE**
- **EXPIRY DATE**
- **LOT NUMBER**
- **RAW MATERIAL DATA**

<table>
<thead>
<tr>
<th>SHIP DATE</th>
<th>MANUFACTURER GLN - A</th>
<th>WHOLESALER GLN - B</th>
<th>RETAIL CHAIN WAREHOUSE GLN - C</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/1/09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2/15/09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/1/09</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SHIP FROM</th>
<th>WHOLESALER GLN - B</th>
<th>RETAIL CHAIN WAREHOUSE GLN - C</th>
<th>RETAIL STORE GLN - D</th>
</tr>
</thead>
<tbody>
<tr>
<td>MANUFACTURER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHOLESALER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RETAIL CHAIN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WAREHOUSE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLN - B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLN - C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLN - D</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RECEIVED DATE</th>
<th>2/8/09</th>
<th>2/20/09</th>
<th>3/10/09</th>
</tr>
</thead>
</table>

**NDC ➔ GTIN:**
(01) 00314141999995
**SERIAL NUMBER**: 165APX3E

**GLN Registry for Healthcare®**
- **GLN - B**: (1100004570208)
- **WHOLESALER NAME**
- **ADDRESS**
- **PHONE NUMBER**
- **ETC**

**SN:**
- **MANUFACTURER**
- **TIN**: (01) 00314141999995
- **RAND**
- **TRENGTH**: 25mg
- **1000 PILLS**
- **TC**

**GDSN:**
- **MANUFACTURER**
- **BRAND**
- **STRENGTH**: 25mg
- **1000 PILLS**
- **ETC**

---

© 2008 GS1 US
NDC ➔ GTIN: (01) 00314141999995
SERIAL NUMBER: 165APX3E

GDSN:
- MANUFACTURER
- GTIN: (01) 00314141999995
- BRAND
- STRENGTH: 25mg
- 1000 PILLS
- ETC

STATIC DATA

DYNAMIC DATA

Manufacturer’s Database
- GTIN - (01) 00314141999995
- SERIAL NUMBER: 165APX3E
- PRODUCTION DATE
- EXPIRY DATE
- LOT NUMBER
- RAW MATERIAL DATA

<table>
<thead>
<tr>
<th></th>
<th>SHIP DATE</th>
<th>SHIP FROM</th>
<th>SHIP TO</th>
<th>RECEIVED DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2/1/09</td>
<td>MANUFACTURER GLN - A</td>
<td>WHOLESALER GLN - B</td>
<td>2/8/09</td>
</tr>
<tr>
<td></td>
<td>2/15/09</td>
<td>WHOLESALER GLN - A</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td>2/20/09</td>
</tr>
<tr>
<td></td>
<td>3/1/09</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL STORE GLN - D</td>
<td>3/10/09</td>
</tr>
</tbody>
</table>

TRACEABILITY
- EPCIS
- DISCOVERY SERVICES

GLN Registry for Healthcare®
- GLN - B (1100004570208)
- WHOLESALER NAME
- ADDRESS
- PHONE NUMBER
- ETC

STATIC DATA
**GLN Registry for Healthcare®**
- GLN - B (1100004570208)
- WHOLESALER NAME
- ADDRESS
- PHONE NUMBER
- ETC

**GDSN:**
- MANUFACTURER
- GTIN: (01) 00314141999995
- BRAND
- STRENGTH: 25mg
- 1000 PILLS
- ETC

**Dynamic Data**
- GDSN:
  - MANUFACTURER
  - GTIN: (01) 00314141999995
  - BRAND
  - STRENGTH: 25mg
  - 1000 PILLS

**Ship Date**
- 2/1/09
- 2/15/09
- 3/1/09

**Ship From**
- MANUFACTURER
  - GLN - A
- WHOLESALER
  - GLN - B
- RETAIL CHAIN WAREHOUSE
  - GLN - C

**Ship To**
- WHOLESALER
  - GLN - B
- RETAIL CHAIN WAREHOUSE
  - GLN - C
- RETAIL STORE
  - GLN - D

**Received Date**
- 2/20/09
- 3/10/09

**Manufacturer’s Database**
- GTIN - (01) 00314141999995
- SERIAL NUMBER: 165APX3E
- PRODUCTION DATE
- EXPIRY DATE
- LOT NUMBER
- RAW MATERIAL DATA

**Traceability**
- EPCIS
- DISCOVERY SERVICES
**STANDARDS IN ACTION**

**Manufacturer’s Database**
- GTIN: (01) 00314141999995
- SERIAL NUMBER: 165APX3E
- PRODUCTION DATE
- EXPIRY DATE
- LOT NUMBER
- RAW MATERIAL DATA

<table>
<thead>
<tr>
<th>SHIP DATE</th>
<th>2/1/09</th>
<th>2/15/09</th>
<th>3/1/09</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHIP FROM</td>
<td>MANUFACTURER GLN - A</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
</tr>
<tr>
<td>SHIP TO</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td>RETAIL STORE GLN - D</td>
</tr>
<tr>
<td>RECEIVED DATE</td>
<td>2/8/09</td>
<td>2/20/09</td>
<td>3/10/09</td>
</tr>
</tbody>
</table>

**TRACEABILITY**
- EPCIS
- DISCOVERY SERVICES
**GS1 Standards in Action**

**GDSN:**
- MANUFACTURER
- GTIN: (01) 00314141999995
- BRAND
- STRENGTH: 25mg
- 1000 PILLS
- ETC

**Manufacturer’s Database**
- GTIN - (01) 00314141999995
- SERIAL NUMBER: 165APX3E
- PRODUCTION DATE
- EXPIRY DATE
- LOT NUMBER
- RAW MATERIAL DATA

<table>
<thead>
<tr>
<th>SHIP DATE</th>
<th>MANUFACTURER</th>
<th>WHOLESALER</th>
<th>RECEIVED DATE</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/1/09</td>
<td>GLN - A</td>
<td>GLN - B</td>
<td>2/8/09</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
</tr>
<tr>
<td>2/15/09</td>
<td></td>
<td>GLN - B</td>
<td>2/20/09</td>
<td>RETAIL STORE GLN - D</td>
</tr>
<tr>
<td>3/1/09</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Traceability**
- EPCIS
- DISCOVERY SERVICES
Contents

• The Fundamentals – cont.

• Significant Events

• Quality

• Pedigree future (DPMS, EPCIS, Discovery)

• Business Benefits and New Processes
Strategy #3: Support adoption of Product Serialization and Pedigree Capability

Initiative highlights:

- Data Alignment Issue resolution

---

Traceability Adoption

- Can that use
- Break Even
- Parceled
- Less Than
- SSCE-18
- SSCE-06
- Homogeneous Pallet
- Full Homogeneous Case
- Homogenous Pallet with Partial Case
- Mixed Pallet (Fix Part)
- Barcode
- Differ Data Site
- SSGC-06
- Homogeneous Case
- Add Mixed Pallet
- Homogeneous Pallet
- Rack Location
- Shelf Location
- Same SSSCG/Ne SSCE
- Print/Print
- Barcode
- Text Backup
- Human-Readable
- AI(01) AII(21)
- 2-D Data Matrix
- ECC200 format
- Al(01): Ai(21) data encoded

---
Contents

• The Fundamentals

• Significant Events

• Quality

• Pedigree future (DPMS, EPCIS, Discovery)

• Business Benefits and New Processes
U.S. Healthcare Community Initiatives

4/16/09

FDA Pharma
Unique
Identifier
Comments
Due

2/1/09
Barcode &
RFID
Interoperability
Paper
Published

2/12/09
FDA UDI
Public
Workshop

6/1/09
Proposed
UDI Reqs Pub
by FDA

6/30/10
GS1
GTIN
Stds Pub

6/1/10
Final FDA
UDI Stds

5/31/09
GHX
Gulf
certified
Pharmacist
Tool

4/10
Pub of FDA
Pharma Stds
(Serialization,
Authentication,
Verification,
Traceability)

12/31/10
2010 GLN
Sunrise

12/31/12
2012 GTIN
Sunrise

1/1/15
CA Pedigree
(50% Mfg Prod)

7/1/16
CA Pedigree
(100% Mfg Prod)

7/1/16
CA Pedigree
(Wholesalers)

7/1/17
CA Pedigree
(Retail/Hos.
Pharmacies)
U.S. Healthcare Community Initiatives

2/16/2009

12/31/10
2010 GLN Sunrise

6/1/09
Proposed UDI Req Pub by FDA

2/1/09
Barcode & RFID Interoperability Paper Published

2/12/09
FDA UDI Comments Due

4/1/09
Pharma Unique Identifier Comments Due

5/31/09
GHX certifed Data Pool

4/10
Pub of FDA Pharma Stds (Serialization, Authentication, Verification, Traceability)

6/1/10
Final FDA Pub of UDI Stds

2012 GTIN Sunrise

12/31/12

1/1/15
CA Pedigree (50% Mfg Prod)

7/1/16
CA Pedigree (Wholesalers)

7/1/17
CA Pedigree (Retail/Hos. Pharmacies)
What is the Provider Pain?
Too many identifiers for the same healthcare location -- confusion, finger pointing, inefficiency

SAINT JOHN’S QUEENS HOSPITAL
1100004570208

ST JOHN’S QUEENS HOSPITAL
100084547

SAINT JOHNS QUEENS HOSPITAL
JAOE

SAINT JOHN’S QUEEN’S HOSPITAL
CA2053

ST. JOHN’S QUEENS HOSPITAL
OM 12345

Many different names
different location numbers
for 1 hospital
2010 GLN Sunrise

"Adoption of GLN in healthcare by 2010*"

GLNs (Unique Location Identifier):

- Assigned by location owners.
- Used in appropriate business transactions and processes between trading partners.
- Hierarchy defined and maintained by location owners.
- GLN Registry for Healthcare® used to facilitate correct location identification.

* December 2010
## 2010 GLN Sunrise

### Adoption of GLN in healthcare by 2010

**Voluntary US Healthcare Implementation Path**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
<th>Reconciliation</th>
<th>Transaction</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Awareness</strong></td>
<td>SC leaders and staff know about GLNs, benefits, and standards in general, and commit to implement.</td>
<td>Organization accesses the GLN Registry, establishes users/approvers and reviews their hierarchy.</td>
<td>Organizations commit to utilize the GLN Registry for rosters/membership maintenance.</td>
<td>Data is maintained in the GLN Registry in “real” time to facilitate ongoing data quality and transactional efficiency.</td>
</tr>
<tr>
<td><strong>Provider</strong></td>
<td>Enumerates locations to ship-to level with GLN. “Certifies” accuracy of data and maintains in “real-time”.</td>
<td>Provider maintains data in registry “real” time.</td>
<td>Place orders using GLNs.</td>
<td>Maintain GLN hierarchy in registry “real” time, resulting in database or record for business partners’ communication.</td>
</tr>
<tr>
<td><strong>GPO</strong></td>
<td>Assists member organizations with enumeration strategy and transitions ownership of GLNs to provider. Enumerates locations to ship-to level with GLN.</td>
<td>GPO stops using internal ID on rosters as providers certify their hierarchy and publish “GLN Only” roster membership lists to business partners.</td>
<td>Roster and fees using GLNs.</td>
<td>Becomes final arbiter of GLN and all disputes are adjudicated via provider.</td>
</tr>
<tr>
<td><strong>Distributor</strong></td>
<td>Assists member organizations with enumeration strategy when required. Enumerates locations to ship-to level with GLN.</td>
<td>Begin to utilize GLN to identify business partners in internal systems.</td>
<td>Take orders from providers. Send rebates/sales tracings to manufacturers using GLN. Communicate with GPOs using GLN.</td>
<td>Maintain info in systems utilizing GLN, ship/order/sales tracing/contracts. Access registry to maintain location information and accept final judgment of provider on accuracy of GLN.</td>
</tr>
<tr>
<td><strong>Manufacturer</strong></td>
<td>Assists member organizations with enumeration strategy when required. Enumerates locations to ship-to level with GLN.</td>
<td>Begin to utilize GLN to identify business partners in internal systems.</td>
<td>Accept orders, rebates/sales tracings via GLN. Report to GPO and Admin - fees via GLN. Communicate with distributors using GLN, including contracts.</td>
<td>Maintain info in systems utilizing GLN, ship/order/sales tracing/contracts. Access registry to maintain location information and accept final judgment of provider on accuracy of GLN.</td>
</tr>
</tbody>
</table>
### Same Product – Different Numbers*

**Industry Distributor Numbers for 3M**

**Product # 8630:**

<table>
<thead>
<tr>
<th>Company</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allegiance</td>
<td>M8630</td>
</tr>
<tr>
<td>Owens &amp; Minor</td>
<td>4509008630</td>
</tr>
<tr>
<td>BBMC-Colonial</td>
<td>045098630</td>
</tr>
<tr>
<td>BBMC-Durr</td>
<td>081048</td>
</tr>
<tr>
<td>Kreisers</td>
<td>MINN8630</td>
</tr>
<tr>
<td>Midwest</td>
<td>TM-8630</td>
</tr>
<tr>
<td>Pacific</td>
<td>3/M8630</td>
</tr>
<tr>
<td>UnitedUMS</td>
<td>001880</td>
</tr>
</tbody>
</table>

* Source: Department of Defense Data Synchronization Study

Nearly every hospital has a different Product ID for 3M 8630! Makes ordering, recalls, and proper identification to the patient difficult.
Same Number Different Products *

Makes Sourcing of needed products difficult and increases errors in ordering and distribution to the patient.

Part Number: 10313
refers to:

- Medtronic's - "NEEDLE CARDIOPLEGIA ADULT 16GA 5/8IN TIP 10IN"
- Hantover's - "CARTRIDGE REPLACEMENT STUNNER YELLOW F/CALVES/HEAVY HOGS"
- Chattanooga Group's - "ACCESSORY TRACTION REPLACEMENT STRAP XL FOR HALTER THORACIC RESTRAINT"
- HF Scientific's - "TEST KIT WATER FREE CHLORINE DPD 25ML SAMPLE PHOTOMETRIC 1000/PK"

Part Number: 1050 refers to:

- 3M Company's - "DRAPE INCISE 35 3/8X 17 5/8IN"
- Tyco's - "PAD TELFA 3 X 4IN STER"

* Source: Premier Inc. Product Item Master
2012 GTIN Sunrise
“Adoption of GTIN in healthcare by 2012*”

**GTINs (Unique Product Identifier):**

- Assigned to healthcare products.
- Used in business transactions.
- Marked on appropriate packaging levels.
- Scanned at points-of-delivery to enhance clinical process.
- Used in product returns and recalls.
- Registered in a GS1 GDSN-certified Data Pool.

* December 2012
## 2012 GTIN Sunrise
### Adoption of GTIN by U.S. Healthcare by 2012
#### Voluntary US Healthcare Implementation Path

<table>
<thead>
<tr>
<th>PHASES</th>
<th>Provider / GPO</th>
<th>Distributor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phase One</strong></td>
<td><strong>Awareness</strong></td>
<td>Know GS1 System Standards. Review incoming material and the ability of internal systems to accept.</td>
</tr>
<tr>
<td><strong>Phase Two</strong></td>
<td><strong>Notify Trading Partners</strong></td>
<td>Notify trading partners of need for GTIN, and possibly additional Application Identifiers (e.g. lot number, expiry date, serial number). Notify trading partners of requirement for GS1 Standards from customers.</td>
</tr>
<tr>
<td><strong>Phase Three</strong></td>
<td><strong>Contract &amp; Systems Gating event</strong></td>
<td>Terms and condition of contracts specify applicable GS1 Standards, specifically GTINs. The Information Technology staff begins to align internal systems to GS1 specifications. Initial testing begins.</td>
</tr>
<tr>
<td><strong>Phase Four</strong></td>
<td><strong>Transactions</strong></td>
<td>Testing continues to use GTINs and other GS1 Standards in a majority of, if not all, transactions.</td>
</tr>
<tr>
<td><strong>Phase Five</strong></td>
<td><strong>2012 Implementation</strong></td>
<td>All products ordered and received are marked in accordance with GS1 Standards.</td>
</tr>
</tbody>
</table>
# 2012 GTIN Sunrise

**Adoption of GTIN by U.S. Healthcare by 2012**

**Voluntary US Healthcare Implementation Path**

<table>
<thead>
<tr>
<th>PHASES</th>
<th>Suppliers</th>
<th>Software Providers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phase One</strong></td>
<td>Know of impending requirement. Determine the ability to meet or exceed requirement.</td>
<td>Notify trading partners of ability to accept GS1 Standards; specifically GTIN and possibly additional Application Identifiers (e.g. lot number, expiry date, serial number). Notify trading partners of requirement for GS1 Standards from customers.</td>
</tr>
<tr>
<td><strong>Phase Two</strong></td>
<td>Notify trading partners of ability to accept GS1 Standards; specifically GTIN and possibly additional Application Identifiers (e.g. lot number, expiry date, serial number). Notify trading partners of requirement for GS1 Standards from customers.</td>
<td>Terms and conditions of contracts call for GS1 Standards on all products: GTIN and possibly lot number, expiry date and serial number. The Information Technology staff begins to align internal systems with this requirement. Initial testing begins.</td>
</tr>
<tr>
<td><strong>Phase Three</strong></td>
<td>Terms and conditions of contracts call for GS1 Standards on all products: GTIN and possibly lot number, expiry date and serial number. The Information Technology staff begins to align internal systems with this requirement. Initial testing begins.</td>
<td>Testing continues to use GTINs and other GS1 Standards in a majority of, if not all, transactions.</td>
</tr>
<tr>
<td><strong>Phase Four</strong></td>
<td>Testing continues to use GTINs and other GS1 Standards in a majority of, if not all, transactions.</td>
<td>All products ordered and received are marked in accordance with GS1 Standards.</td>
</tr>
<tr>
<td><strong>Phase Five</strong></td>
<td>All products ordered and received are marked in accordance with GS1 Standards.</td>
<td>2012 Implementation</td>
</tr>
</tbody>
</table>
Contents

• The Fundamentals

• Significant Events

• Quality

• Pedigree future (DPMS, EPCIS, Discovery)

• Business Benefits and New Processes
Bar Code Quality

Where do all those measurements come from? . . . Verification!
Bar Code Quality
Test Card for ISO/ANSI Based Verifiers

• Calibrated Conformance Standard is used to “verify the verifier”

• Traceable to National Institute of Standards and Technology (NIST)

• Important training tool for personnel in the correct use of verifiers

• Stops all arguments
Bar Code Quality

Verifying the Verifier:

Calibrated Conformance Standard Test Cards

These cards stop all arguments and put you and your customer on the same page!
Bar Code Quality
What this does for you is:

• Prevents you from sending “bad” bar codes into the supply chain!

• Ensures readability of your bar codes throughout the supply chain.

• Lets you know what’s happening before it’s too late!
Contents

• The Fundamentals

• Significant Events

• Quality

• Pedigree future (DPMS, EPCIS, Discovery)

• Business Benefits and New Processes
### Manufacturer’s Database

- **GTIN** - (01) 00314141999995
- **SERIAL NUMBER** - 165APX3E
- **PRODUCTION DATE**
- **EXPIRY DATE**
- **LOT NUMBER**
- **RAW MATERIAL DATA**

<table>
<thead>
<tr>
<th>SHIP DATE</th>
<th>SHIP FROM</th>
<th>SHIP TO</th>
<th>RECEIVED DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/1/09</td>
<td>MANUFACTURER GLN - A</td>
<td>WHOLESALER GLN - B</td>
<td>2/20/09</td>
</tr>
<tr>
<td>2/15/09</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td>3/1/09</td>
</tr>
<tr>
<td>3/1/09</td>
<td>RETAIL STORE GLN - D</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td></td>
</tr>
</tbody>
</table>

### Traceability

- **EPCIS**
- **DISCOVERY SERVICES**
### Manufacturer’s Database
- GTIN - (01) 00314141999995
- SERIAL NUMBER: 165APX3E
- PRODUCTION DATE
- EXPIRY DATE
- LOT NUMBER
- RAW MATERIAL DATA

### Traceability
- EPCIS
- DISCOVERY SERVICES

<table>
<thead>
<tr>
<th>SHIP DATE</th>
<th>SHIP FROM</th>
<th></th>
<th>SHIP TO</th>
<th></th>
<th>RECEIVED DATE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2/1/09</td>
<td>MANUFACTURER GLN - A</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td>2/8/09</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
</tr>
<tr>
<td>2/15/09</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td>2/20/09</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NDC ➔ GTIN: (01) 00314141999995
SERIAL NUMBER: 165APX3E

**GLN Registry for Healthcare®**
- GLN - B (1100004570208)
- WHOLESALER NAME
- ADDRESS
- PHONE NUMBER
- ETC

**Dynamic Data**
- MANUFACTURER
- GTIN: (01) 00314141999995
- BRAND
- STRENGTH: 25mg
- 1000 PILLS
- ETC

© 2008 GS1 US
### Manufacturer's Database

- **GTIN** - (01) 00314141999995
- **SERIAL NUMBER**: 165APX3E
- **PRODUCTION DATE**
- **EXPIRY DATE**
- **LOT NUMBER**
- **RAW MATERIAL DATA**

### Traceability

- **EPCIS**
- **DISCOVERY SERVICES**

### Table: Product Movement

<table>
<thead>
<tr>
<th>SHIP DATE</th>
<th>SHIP FROM</th>
<th>SHIP TO</th>
<th>RECEIVED DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/1/09</td>
<td>MANUFACTURER GLN - A</td>
<td>WHOLESALER GLN - B</td>
<td>2/8/09</td>
</tr>
<tr>
<td>2/15/09</td>
<td>WHOLESALER GLN - B</td>
<td>RETAIL CHAIN WAREHOUSE GLN - C</td>
<td>2/20/09</td>
</tr>
<tr>
<td>3/1/09</td>
<td>RETAIL STORE GLN - D</td>
<td></td>
<td>3/10/09</td>
</tr>
</tbody>
</table>

**GDSN:**
- MANUFACTURER
- GTIN: (01) 00314141999995
- BRAND
- STRENGTH: 25mg
- 1000 PILLS
- ETC

**NDC ➔ GTIN:**
(01) 00314141999995
SERIAL NUMBER: 165APX3E

**GLN Registry for Healthcare®**
- GLN - B (1100004570208)
- WHOLESALER NAME
- ADDRESS
- PHONE NUMBER
- ETC

**Static Data**

**Dynamic Data**

- Manufacturer's Database
- SHIP DATE
- SHIP FROM
- SHIP TO
- RECEIVED DATE

**Traceability**
- EPCIS
- DISCOVERY SERVICES
Today - Pedigree
Using Current Standards

Pedigree
Contains redundant
Product and
Location Data

Manufacturer

Wholesaler

Provider

Pedigree
Reliable movement & Disposition

Who

What

Where

When

Why

© 2008 GS1 US
Tomorrow – Track and Trace
Using **Emerging Standards**

**Who**
- Manufacturer
- Wholesaler
- Provider

**GiN Registry**
- Reliable Location Hierarchy

**GDSN**
- Reliable Product Descriptions

**Discovery Service**
- Reliable Lookup and Authentication

**EPCIS & Pedigree**
- Reliable movement & Disposition

© 2008 GS1 US
Tomorrow – Track and Trace
Using Emerging Standards

Product ID: 03567896538962
Lot #: 694184

Duplicate Product
Tomorrow – Track and Trace

- IV Pump
  - Ready for Use
  - Needs Maintenance
- Wheelchair
Contents

• The Fundamentals

• Significant Events

• Quality

• Pedigree future (DPMS, EPCIS, Discovery)

• Business Benefits and New Processes
The Practice of Inference

U.S. Pharmaceutical Supply Chain Regulatory Environment

The practice of inference is a critical component of the U.S. pharmaceutical industry. Inference is defined as the process by which data is analyzed to draw conclusions or make decisions in the absence of complete information. This paper explores the various aspects and considerations involved in the practice of inference within the pharmaceutical sector.

Motivation of Inference

- Economic drivers: The pharmaceutical industry is driven by the need for efficient and cost-effective decision-making.
- Compliance drivers: Ensuring regulatory compliance and maintaining quality standards are paramount in the industry.
- Supply chain challenges: The complexity of the supply chain requires intelligent decision support to optimize operations.

Applications of Inference

- Quality assurance: Inference helps in identifying potential quality issues before they escalate.
- Predictive analytics: Predictive models can infer future trends and outcomes.
- Decision support: Inference enables informed decision-making based on available data.

The Practice of Inference

- Data-driven decisions: Inference leverages data to make informed decisions.
- Risk management: Inference helps in assessing risks and developing mitigation strategies.
- Process optimization: Inference can optimize processes to improve efficiency and reduce costs.

Inference on a General Concept

Inference is a critical aspect of the U.S. pharmaceutical supply chain. It is defined as the process by which data is analyzed to draw conclusions or make decisions in the absence of complete information. Inference is used to manage risk, enhance compliance, and improve operational efficiency within the supply chain.

Economic drivers for inference include the need for efficient and cost-effective decision-making,而 Compliance drivers require ensuring regulatory compliance and maintaining quality standards. Supply chain challenges necessitate intelligent decision support to optimize operations.

Applications of inference include quality assurance, predictive analytics, and decision support. Quality assurance benefits from inference in identifying potential quality issues, while predictive analytics leverage inference to anticipate future trends and outcomes. Decision support enhances informed decision-making based on available data.


Inference is essential in ensuring the safety and reliability of pharmaceutical products, thus maintaining patient safety. Efficient movement of products through the supply chain requires the precise application of inference to reduce errors, increase operational efficiency, and minimize the risk of delays. The practice of inference plays a crucial role in the pharmaceutical industry, ensuring compliance with regulations and enhancing overall operational effectiveness.
Security and Privacy Task Force

Work in Process
Traceability Adoption

Benefits beyond Regulatory Compliance

Business benefits of serialization and granular events data
Questions?

Bob Celeste
Director, Healthcare
GS1 Healthcare US
rceleste@gs1us.org
Drug Supply Chain Integrity Strategy

John Danese
Strategy Director, Life Sciences Applications

Prepared for California State Board of Pharmacy
March 11, 2009
Safe Harbor Statement

The following is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decision. The development, release, and timing of any features or functionality described for Oracle’s products remains at the sole discretion of Oracle.
Update on Drivers

- **US States**
  - CA ePedigree law now 1/1/15 and federal preemption language
  - FL and other states are enforcing pedigree-only regulations today
- **US Federal**
  - FDA Amendments Act
    - Develop standards for UID and authentication tools by April 2010
  - FDA Globalization Act
    - Pilot for foreign finished drugs and ingredients announced
- **EMEA**
  - Italy, Belgium, others requiring serialization today
  - Turkey begins tracking serials mid-2009
  - EFPIA (European Federation of Pharmaceutical Industry Associations) has been working on a program to authenticate products at point of sale. 2009 pilot
- **GS1 Healthcare**
  - Global Traceability Standard for Healthcare
What are Manufacturers Doing?

• We’ve seen a range of responses customers
  • Forge ahead with serialization efforts and lighten up effort around pedigree
  • Refocus on EU products and serialization
  • Wait and see – put projects on hold and do nothing

• Those continuing on current pace because serialization is inevitable
  • They want control, rather than going down a path of trying to guess the next regulatory move
  • Many assume / hope there will be US federal action so they don’t have to address different requirements state-to-state

…but there is considerable uncertainty about what the Fed will do
“Current view is that this was an entirely compliance and risk-based activity, but we are now looking at the cost of returns as well”

“[The solution set we are piloting] lacks robustness, maturity and functionality”

“We’re putting out bets on the EFPIA approach in Europe”

“We’re addressing the near-term European requirements on a case-by-case basis, until the regulatory environment settles down and it makes more sense to take a more strategic global approach.”

- Large Pharma VP of Business Services

“Returns/recall mgmt is one of the motivators for the project”

“We are planning to make a vendor choice by end of 2009 and begin serialization implementation in early 2010”

“Frankly, we have been cribbing many of our requirements from what we know about the Oracle pedigree and serialization strategy in our discussions with business leaders”

“I polled fellow pharma and biotech CIOs in the area. They are focusing on serialization and waiting for ePedigree requirements to clear up.”

- Mid-Sized Pharma, CIO
What Our Customers are Saying

“We’re focusing on FL and TX, but are concerned about PDMA enforcement, so we’re making sure we have ADR with all of our manufacturers.”

“We’re concerned about the different ways we could receive data from our partners…bar code standards, on-product markings, pedigree data.”

-Large Distributor, Regulatory Affairs Project Mgr.

“We are focusing on enabling serialization for our products on our packaging lines and in our distribution locations to make sure we can sell into Europe and to be prepared for what happens in the US”

-Large Pharma/OTC, Sr. eCommerce Analyst

“Our CMO partner is starting over with their pedigree and serialization pilot due to viability problems with their solution provider. We are now considering taking this on in-house. We’d would seriously consider Oracle if a solution were available by 2009 or early 2010”

-Small Pharma (outsources mfg) Director of SCM
Urgency Around Serialization Remains High

Survey Finds U.S. Biopharm Industry Is Moving Steadily Toward Secure Distribution

67% of Respondents Reported Project Stage or Already Underway Despite Mandated Regulations

MAMMOTH, N.Y. & PALO ALTO, Calif. — Pharmapac announced survey results reporting the U.S. biopharmaceutical industry's continued move toward serialization and addressing related supply chain requirements. The research was conducted by the Blue Ocean Group and included a survey of 1200 U.S. biopharmaceutical companies. The majority of respondents indicated that their companies are in the process of moving toward serialization.

The industry is experimenting with the latest technologies and business processes to achieve this goal, said Mike Gardner, vice president of product management for Pharmapac. "The survey results confirm the strong belief that serialization benefits the entire supply chain, from manufacturer to patient," he said. "By implementing serialization, companies can ensure product protection and reduce the risk of diversion—irrespective of legislative mandates."

Highlights from the survey results:

- On the key question, "My organization's status for implementing item-level serialization," 67% of manufacturers reported they are currently moving forward with their serialization efforts:
  - 12%: Currently serializing at least one product in commercial distribution
  - 12%: Conducting a production-scale pilot
  - 43%: Planning to initiate a pilot in the next 12 months
  - 14%: No plans
  - 15%: I don't know/other

The question, "My perception of item-level serialization in my organization," 61% responded that the technology is either an "important compliance objective" or "an opportunity to derive business value beyond compliance" or both; 10% responded that it was just a business cost requiring quick and inexpensive compliance while 9% reported they either did not know or had no opinion. When asked to identify the number one business benefit of adopting serialization, the top answer given was "to enhance our reputation with customers and the public," followed closely by "detecting counterfeiting," "greater inventory visibility," and "improving our returns process."
Value Proposition of Supply Chain Integrity
Business Benefits in Addition to Regulatory Compliance

- Global Counterfeiting exceeds $50B
- Impacts 3.4B prescriptions annually in US
- As much as 1%, or 34M doses could be counterfeit
- Systems to authenticate product
- Protect brand integrity
- Recall Management
- China effect – Heparin, Melamine, Lead

Product Integrity

- Diverted product impacting profitability
- Parallel trade
- Inventory shrinkage and damage control
- Identification/reporting of suspect shipments

Returns

- $2B+ / year and climbing at 10% rate
- Controlling/Validating returns
  - Systems to detect counterfeits
  - Assess and authorize valid returns

Channel Integrity

Regulatory Compliance

- US State by State regulations
- FDA Amendments / Globalization Acts
- European Commission Pedigree / Authentication
- Serialization initiatives in Turkey, Italy, Belgium, etc.
- European Federation of Pharmaceutical Industries & Associations (EFPIA)
Supply Chain Integrity – Returns Repudiation

- $2B+ / year and climbing at 10% rate
- In US, estimated 5% of line volume is returned to the manufacturer*
  - One large branded pharma alone spends $400M per year on return credit
    - Estimates 50% are illegitimate
    - Counterfeit
    - Returned at higher price than invoice
    - Product not purchased from manufacturer
    - Expired product (“distributor offloads before expiry date”)
- Current industry order fulfillment data tracking cannot detect illegitimate returns
  - Lots span multiple days/weeks/months of production
  - No way to track return to original sales order, shipment or invoice
- Serialization allows a link between the return receipt and the original shipment/invoice

*Source: California Board of Pharmacy estimates 2008
Oracle Pedigree and Serialization Manager
Ensure Supply Chain Integrity

• WHAT – An integrated mass-serialization and pedigree application that enables companies to implement mass-serialization of drug products and share serialized product data.

• HOW – Mass serialization management based on US (CA, FL, Federal) and international standards (GS1 Healthcare), regulations and industry consortium initiatives (EFPIA). Accessibility to data through role based application user interface, portal, web services, and file exchange along with business analytics for counterfeit threat assessment.

• RESULTS – Protect public health; Achieve compliance with global electronic pedigree, serialization, track & trace and product authentication regulations and industry mandates through product (and ingredient) data sharing; Protect brand integrity; Cost savings through validation of returns.
Deliver Out-of-the-Box Integration
Maximize Return on Investment & Reduce Complexity

• WHAT – A process integration pack to support integration of OPSM with Oracle and 3rd party manufacturing, packaging and logistics systems

• HOW – Populate OPSM with reference data from one or more existing back end systems and trigger serialization management from receipts, returns, shipments and packaging

• RESULTS – Integrated and reusable Oracle solution that delivers lower initial and ongoing TCO compared to EPCIS and pedigree-only solutions
Challenges of Existing Solutions

EPCIS is a generic communications framework & data model, not an application

1. Custom Development Required
   - Customers have to build their own user interfaces, functional flows, system interfaces, labeling & serial generation logic
   - Customer1 “The integration is bigger than any app we are integrating to”
   - Customer2 “Splitting solution into pedigree and EPCIS is not scalable”

2. Not Industry Specific
   - EPCIS is built to store generic serial numbers, no concept of other pharmaceutical requirement such as lot control, Electronic Records & Signatures & other compliance requirements

3. Lack of Exception Management
   - Not built for industry use cases, can’t handle pharmaceutical exceptions – e.g., what if you don’t receive what the pedigree says

4. Still Need a Pedigree System
   - Additional product and integrations for pedigree
Oracle Pedigree & Serialization Manager
Interoperable Solution for Serialization & Pedigree Management

Oracle Fusion Middleware
BAM – Business Activity Monitoring
BPEL – Business Process Execution Language

Oracle Database

Legacy Transactional System

Oracle Application Integration Architecture

Oracle Pedigree & Serialization Manager

- ePedigree creation
- ePedigree update
- Serial management
- Part 11-compliant authentication
- Inquiry / Reporting
- Works with your existing inventory solution (RFID or 2D barcode based)
Drug Supply Chain Integrity
Serialization and ePedigree Management Application

**6 Returns Reconciliation**
- Import returned serials
- Reconcile serials against sales orders
- Assess and authorize valid returns
- Serial disposition

**5 Track & Trace**
- Portal for customer and consumer serial verification
- Mobile access
- Flag counterfeit serials
- Protect public health

**1 Serialization**
- Unit and case mass serialization
- Multi-site provisioning
- Serial import and export
- Contract manufacturing serial data exchange
- Custom serial algorithms

**2 Packaging**
- Web services integration to packaging systems
- Packaging hierarchy maintenance UI and services
- Serial and packaging inquiry

**3 Shipping**
- Outbound serial and pedigree management
- Shipment and serial analytics
- Export product data to regulatory database(s)

**4 Receiving**
- Inbound serial and pedigree management
- BI dashboard drilldown into receipt and serial details

**Comply, Track, Trace, Protect**
Oracle Pedigree and Serialization Manager
Built with Users and Other Systems In Mind

User Interface

System Setup
- System Parameters
- Locations
- Products
- Serial Ranges
- Lots

Packaging Workspace
- Find Package
- Pack / Unpack
- Associate Serials to Package
- Assign Package Ids
- Packaging Level Serial Disposition

Serials Workspace
- Find Serials
- Maintain Serials
- Inactivate Serials
- Serials Mass Update
- Export Serials
- Flag Counterfeits

Transaction Workspace
- Find Transactions
- View Serials
- Transaction History
- Transaction Details
- Manage Exceptions
- Associate Serials
- Export Serials

Web Services
- Generate Serials
- Create Serials
- Update Serials
- Inactivate Serials
- Get Serials
- Send Serials
- Pack
- Unpack
- Add Shipment
- Add Return
- Cancel Return

File Transfer
Partner / Consumer Serial Validation Portal

- Manufacturers get additional views into where their product is consumed
- Customers can verify serial authenticity
- Customers can check for holds, expiration or recalls by lot or serial
### Serialization / Packing

![Diagram showing steps from manufacturing to shipping with Saleable Unit, Box, Case, and Container stages.]

#### Product Packaging

<table>
<thead>
<tr>
<th>Level</th>
<th>Serial Number</th>
<th>Type</th>
<th>Packaging Hierarchy</th>
<th>Category</th>
<th>OPSM Serialized</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3.000037.1000209.000000000001</td>
<td>SGTIN-96</td>
<td>Blister Pack / Bottle / Vial</td>
<td>Serialized Product</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>2.000037.2000209.000000001001</td>
<td>SGTIN-96</td>
<td>Case</td>
<td>Serialized Product</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>2.000037.3000209.000000001201</td>
<td>SGTIN-96</td>
<td>Case</td>
<td>Serialized Product</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>(00)5 000037 0000000001</td>
<td>SCC-18</td>
<td>Pallet</td>
<td>Serialized Packaging</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>000037.5 0000000001</td>
<td>SCC-96</td>
<td>Container</td>
<td>Serialized Packaging</td>
<td>No</td>
</tr>
</tbody>
</table>
Multiple Product Packaging IDs

SSCC-96 0000037 8 0000000001

SSCC-18 (00)5 000037 0000000001 3
SSCC-96 0000037 5 0000000001

SGTIN-96 3015.0000374.3000209.000000001201
GTIN 40000373000209
UPC 373000209

SGTIN-96 3015.000037.2000209.000000001001
GTIN 20000372000209
UPC 372000209

SGTIN-96 3015.00003701000209.000000000002
GTIN 00000371000209
UPC 371000209

SGTIN-96 3015.00003701000209.000000000001
GTIN 00000371000209
UPC 371000209
Why Supply Chain Integrity Management?

It is Important
- Consumer Safety
- Brand Protection
- Problems are always Urgent

It is Universal
- Multi Industry
  - Pharma, CG, Food & Beverage, High Tech
- Multi Enterprise
  - Manufacturers, Distributors, Retailers

It is Hard
- Multi Instance IT Structures
- Lack of lot & serial control in many industries
- High volume -> requires scalability
Oracle Pedigree & Serialization Manager

Purpose-built for and with the pharma industry

Serialization and pedigree management in a single solution

Delivering regulatory compliance and business value
Contact Us

John Danese
Director, Life Sciences Product Strategy
John.danese@oracle.com
(914) 239-3788
ORACLE IS THE INFORMATION COMPANY